Introduction {#sec1-1}
============

Glaucoma is one of the world\'s leading causes of irreversible blindness and is characterized by progressive optic nerve damage and selective loss of retinal ganglion cells (RGCs) (Diekmann et al., 2013; Zhong et al., 2013). Current therapies have focused on lowering intraocular pressure and slowing disease progression (Baudouin et al., 2013). Although the RGC cell body is localized in the eye, the large part of its axon lies outside the eye, forming the optic nerve, chiasm, and optic tract. Ninety percent of the RGCs terminate in the lateral geniculate nucleus (LGN), the major relay station between the retina and visual cortex (Gupta et al., 2009; Ito et al., 2009). In experimental glaucoma with optic nerve fiber loss, the LGN undergoes degeneration, including overall LGN shrinkage and reduced neuronal size and number (Ito et al., 2011). These findings provide evidence that the pathology of glaucomatous may involve RGC loss and LGN degeneration.

Heat shock protein (HSP) is a well-conserved, ubiquitous protein found in all cells (Urbak et al., 2010; Lomiwes et al., 2014). Zinc sulfate significantly induces the expression of HSP72, whereas quercetin inhibits its expression. The inhibitor of c-Jun N-terminal kinase (JNK), SP600125, has been shown to specifically block the stress-activated kinase (SAPK)/JNK pathway reducing apoptosis of ganglion cells (Glushkova et al., 2013). HSPs are normally present at low levels, but their expression is rapidly increased in response to a variety of harmful stimuli, including hypoxia or ischemia (or other types of metabolic stress) and temperature elevation (O'Reilly et al., 2010). This stress response is thought to be vital in the intracellular chaperoning function to protect cells from death. Neurons of transgenic mice expressing HSP72 or those of rats injected with the herpes virus containing HSP72 genes have also been shown to be resistant to ischemia and seizures, which suggests that HSP72 is important for neuroprotection (Nagashima et al., 2011; Barreto et al., 2012; Abdi et al., 2013).

We have shown that HSP72 is induced in RGCs of rat acute glaucoma models with heat stress or zinc sulfate administration (Qing et al., 2004). Further, the dynamics of HSP72 induction between these two groups are quite different. In the present study, we investigated the expression of HSP72 in RGCs and LGN neurons in a rat model of chronic ocular hypertension, and explored the mechanism of HSP72-mediated neuroprotection in glaucoma. These findings may strengthen the current knowledge about the biological significance of HSP72 in behavior, and provide a novel therapeutic strategy against the progression of chronic glaucoma.

Materials and Methods {#sec1-2}
=====================

Animals {#sec2-1}
-------

A total of 140 adult, healthy male Wistar rats, weighing 200--300 g, were supplied by the Animal Breeding Center, Second Xiangya Hospital, Central South University, China (license No. SYXK (Xiang) 2004-0013). The rats were maintained at 21 ± 2°C under a 12-hour light-dark cycle, and were matched for age and weight before each experiment. The pilot project was approved by the Ethics Committees of the Second Xiangya Hospital, Central South University, China.

Animal grouping {#sec2-2}
---------------

All experiments were performed on the right eye. A total of 140 male Wistar rats were divided into five groups: normal control (*n* = 12), damage control (*n* = 48), zinc sulfate (*n* = 30), quercetin (*n* = 30), or SP600125 (*n* = 20). Except normal control group, 128 rats were used to establish chronic glaucoma models. Among them, 48 model rats were killed at different intervals after laser treatment without drug injection, serving as damage controls. Thirty rats were treated with zinc sulfate (Sigma-Aldrich, St. Louis, MO, USA) *via* intraperitoneal injection 2 weeks after laser treatment. Thirty rats were treated with intraperitoneal injection of quercetin 6 hours after laser treatment. Twenty rats were treated with SP600125 (Calbiochem, Merck-Millipore, Darmstadt, Germany) after laser treatment. The treated model rats were sacrificed at specific intervals after treatment, and the right eye immediately enucleated.

Induction of chronic ocular hypertension {#sec2-3}
----------------------------------------

Rats were anesthetized (100 g/L chloral hydrate 3.8 mL/kg, intraperitoneal), then the bulbar conjunctiva was cut and two superficial venous tributaries were burnt by a viridis-lite laser (532 nm). The laser beam, which was directed towards all four episcleral veins and at 360° of the limbal plexus, was applied at 260--300 mW for 200 μs, producing a spot size of 200 µm at the episcleral veins. Intraocular pressure was also measured with Tonopen XL before the operation and 3, 7, 14, and 28 days after the operation. Intraocular pressure that was 40% beyond the preoperative value (9--16 mmHg, 1 mmHg = 0.133 kPa) indicated that the model was successfully established.

Retrograde labeling of regenerating RGCs {#sec2-4}
----------------------------------------

Rats were anesthetized and placed in a stereotactic device. Fluoro-Gold (5%) (Fluorochrome, Denver, CO, USA) injections into the bilateral superior colliculi were administered with the following coordinates: 6.3 and 6.8 mm posterior to bregma, 1.5 mm lateral to midline, and 3.6 and 4.0 mm from the skull. A total of 0.8 μL Fluoro-Gold was applied through a microinjector (Anting, Shanghai, China). Rats were sacrificed 3, 7, 14, or 28 days after intraperitoneal or intracerebroventricular injection. RGC levels were measured 3, 7, 14, and 28 days after treatments. Cells that contained Fluoro-Gold in the cytoplasm and possessed at least one dendrite, or an axon, were counted as axon-regenerating RGCs. Small Fluoro-Gold-labelled cells with identifiable dendrites or axon were also counted as axon-regenerating RGCs. To determine the total number of Fluoro-Gold-labelled RGCs per retina, the number of Fluoro-Gold-labelled RGCs in each field (0.25 × 0.25 mm) at a fixed distance from each other, in a pattern of grid intersections, was counted throughout the whole retina. A total of 70--80 fields (about 8--10% of the retinal area) were sampled per retina.

Immunohistochemistry for HSP72 {#sec2-5}
------------------------------

The eye balls were immersed in a fixative consisting of 4% paraformaldehyde in 0.1 mol/L Sorensen\'s phosphate buffer (pH 7.2) for 4 hours at 4°C then washed (several rinses) in PBS. After the specimens were immersed in 10--20% sucrose (in 0.1 mol/L PBS), they were then embedded for cryo-sectioning. To reduce nonspecific staining, the sections were blocked in a solution containing 4% normal fetal calf serum. Sections were then incubated with the primary antibody, mouse anti-HSP72 polyclonal antibody (1:200; Santa Cruz Biotechnology, Santa Cruz, CA, USA), in blocking solution overnight at 4°C in a humidified chamber. The sections were rinsed three times with PBS and then incubated with the secondary antibody, rabbit anti-mouse IgG (1:500; Boster, Wuhan, Hubei Province, China), in blocking solution for 30 minutes at 37°C. Micrographs of immunolabeled sections were captured using a fluorescence microscope (Carl Zeiss Meditec, Jena, Germany).

Western blot analysis {#sec2-6}
---------------------

Rats were anesthetized at the different time points followed by thoracotomy and left ventricular cannulation, then the dissection of the right atrial appendage, which was pre-cooled at 4°C in saline perfusion until the effluent became clear. The brains were then removed, the LGN tissue separated, and the retina peeled on ice rapidly (Paxinos and Watson, 1997, reprinted with permission from Elsevier). Retinal protein or LGN protein was extracted using RIPA lysis buffer (20 mmol/L Tris, pH 7.5, 150 mmol/L NaCl, 1% Triton X-100, 2.5 mmol/L sodium pyrophosphate, 1 mmol/L EDTA, 1% Na~3~VO~4~, 0.5 µg/mL leupeptin, and 1 mmol/L phenylmethanesulfonyl fluoride). After centrifugation for 10 minutes at 14,000 × g, the supernatant was collected. Cell supernatant was collected after centrifuging at 15,000 r/min for 15 minutes, frozen, and kept at --70°C for later usage. Proteins (5 µg/lane) were subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred to nitrocellulose membranes (Hybond; GE Healthcare, Piscataway, NJ, USA). Membranes were blocked with 5% nonfat dry milk in Tris-buffered saline (TBS; 20 mmol/L Tris, 137 mmol/L NaCl \[pH 7.4\]) containing 0.02% Tween-20 (TBST) followed by the primary antibodies (diluted in TBST): mouse anti-HSP72 monoclonal antibody (1:2,000; Cell Signaling, USA), rabbit anti-p-JNK, or anti-p-c-Jun monoclonal antibodies (both at 1:2,000; Cell Signaling) for 24 hours at 4°C. Membranes were then washed three times with TBST. Rabbit anti-β-actin antibody (1:2,000; Sigma-Aldrich, St. Louis, MO, USA) was used as the loading control in all cases. Membranes were then exposed to horseradish peroxidase-conjugated anti-mouse or anti-rabbit antibody (BAbCo, Berkeley, CA, USA; 1:1,000 in TBST) for 1 hour at room temperature, followed by three washes with TBST. Immunoreactive proteins were visualized using chemiluminescence detection reagents (GE Healthcare) on autoradiograph films. The intensity of each band was quantified using the Scion Image program. Films were scanned and the target zone analyzed with the gel image processing system.

Statistical analysis {#sec2-7}
--------------------

All data are expressed as mean ± SEM and were analyzed by the two-sample *t*-test to compare the differences between treated groups and control groups. All experiments were performed in triplicate. Statistical analysis was performed using SPSS 17.0 software (SPSS, Chicago, IL, USA). *P* \< 0.05 was considered to be statistically significant.

Results {#sec1-3}
=======

Effect of laser treatment on the survival of RGCs in rats following different drug injections {#sec2-8}
---------------------------------------------------------------------------------------------

Fluoro-Gold retrograde labeling results showed the number of RGCs in the damage control, zinc sulfate, quercetin, SP600125 groups was significantly (*P* \< 0.05) lower compared with the normal control group (**[Table 1](#T1){ref-type="table"}**). The number of RGCs was significantly (*P* \< 0.05) higher in the zinc sulfate group compared with the damage control group at 3, 7, 14, and 28 days, and the number of RGCs was significantly (*P* \< 0.05) lower in the quercetin group than that in the damage control group (**[Table 1](#T1){ref-type="table"}**).
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Effect of laser treatment on the expression of HSP72 in RGCs and the LGN of rats following different drug injections {#sec2-9}
--------------------------------------------------------------------------------------------------------------------

Immunohistochemical staining and western blot analysis showed no presence and no expression, respectively of HSP72 in RGCs and the LGN of normal control rats (**[Figure 2A](#F2){ref-type="fig"}, [C](#F2){ref-type="fig"}**). At 7 days after laser treatment, both immunostaining and western blot were performed to detect the expression of HSP72 in the retinal ganglion cell layer, nerve fiber layer, outer plexiform layer and LGN (**[Figure 2B](#F2){ref-type="fig"}**). Moreover, HSP72 expression reached the peak at 7 days in LGN (**[Figure 2D](#F2){ref-type="fig"}**). In ocular hypertension for 28 days group, the expression of HSP72 in both retina and LGN was significantly reduced (**[Figure 2E](#F2){ref-type="fig"}**). These indicated that HSP72, after chronic elevated IOP, was expressed effectively.

![Retinal ganglion cells (RGCs) in rats 28 days after laser treatment (Fluoro-Gold staining, × 200).\
Fluoro-Gold retrograde labeling showing that at 28 days after laser treatment, more RGCs are found in the zinc sulfate group (C) compared with the normal control group (A), and fewer RGCs in the quercetin group (D) was found compared with the damage control group (B--D). (E) SP600125 (c-Jun N-terminal kinase inhibitor) had fewer RGCs compared with normal control group (A).](NRR-9-1395-g002){#F1}

![Effect of laser treatment on the presence and expression of heat shock protein 72 (HSP72) in retinal ganglion cells (RGCs) and the lateral geniculate nucleus (LGN) of rats following different drug injections.\
(A--D) Immunohistochemistry for HSP72. (A) HSP72 is not detected in the normal retina. (B) Compared with the normal control group, the pres-ence of HSP72 (brown staining) is less prominent at 7 days in the retinal ganglion cell layer (thin short arrow), nerve fiber layer (thick arrow) and outer plexiform layer (slender arrow) of the retina. (C) HSP72 is not detected in the normal LGN. (D) Seven days after laser treatment, LGN neurons are detected in tissues that label HSP72 (thin short arrow), vacuolated cells, nuclear condensation (thin arrow), and capillaries (thick arrow). West-ern immunoblot and quantitative analysis of HSP72 protein expression in the RGCs (E, F) and LGN (E, G) at different time points. At 3, 7, 14, and 28 days after laser treatment (II--V), HSP72 protein expression in the retina and LGN is significantly different at each time point (*P* \< 0.05). I: Before treatment (damage control group).](NRR-9-1395-g003){#F2}

Effect of laser treatment on protein expression of phosphorylated c-Jun N-terminal kinases (p-JNK) and phosphorylated c-Jun (p-c-Jun) in the rat retina and the LGN {#sec2-10}
-------------------------------------------------------------------------------------------------------------------------------------------------------------------

Three days after laser treatment, p-JNK and p-c-Jun proteins were mildly expressed in both the retina and LGN of rats from the damage control group. The expression levels reached a peak at 7 days and then maintained a high level. At each time point, the expression of p-JNK and p-c-Jun in the LGN was increased after laser treatment, reached the peak at 14 days, and remained at a high level during the observation time (**[Figure 3](#F3){ref-type="fig"}**).

![Protein expression of phosphorylated c-Jun N-terminal kinases (p-JNK) and phosphorylated c-Jun (p-c-Jun) in retinal ganglion cells (RGCs) and the lateral geniculate nucleus (LGN) of rats following laser treatment.\
Western immunoblot and quantitative analysis of p-JNK and p-c-Jun in the RGCs (A, B) and LGN (A, C) in the damage control group at different time points. Three days after laser treatment, p-JNK and p-c-Jun proteins are mildly expressed in the RGCs and the LGN. The expression levels reach a peak at 7 days and are maintained at a high level. At each time point, the expression of p-JNK and p-c-Jun protein in the LGN increases af-ter laser treatment, reaches a peak at 14 days, and remains at a high level during the observation time. I--V: Before treatment, 3, 7, 14, 28 days after treatment in damage control group.](NRR-9-1395-g004){#F3}

Effects of laser treatment on the protein expression of p-JNK and p-c-Jun in the retina and LGN after drug intervention {#sec2-11}
-----------------------------------------------------------------------------------------------------------------------

After 7--28 days of laser treatment, the expression of p-JNK peaked in the retina of the damage control group (**[Figure 4](#F4){ref-type="fig"}**). Expression of p-JNK in the zinc sulfate, quercetin, and SP600125 groups was significantly increased (*P* \< 0.01; **[Figure 4](#F4){ref-type="fig"}**). The expression of p-JNK was not significantly different between these four groups (**[Figure 4](#F4){ref-type="fig"}**). The expression of p-JNK was not significantly increased in the normal control (**[Figure 4](#F4){ref-type="fig"}**). The expression of p-c-Jun (occurring downstream of p-JNK) was significantly (*P* \< 0.05) different between the damage control, zinc sulfate, quercetin, and SP600125 groups (**[Figure 4](#F4){ref-type="fig"}**). Its level of expression was lowest in the SP600125 group, followed by the zinc sulfate group and then the damage control group, with the highest expression occurring in the quercetin group (*P* \< 0.05; **[Figure 4](#F4){ref-type="fig"}**). The expression of p-c-Jun in the normal control group was almost undetectable (**[Figure 4](#F4){ref-type="fig"}**). In the LGN, the expression of p-JNK and p-c-Jun reached its peak at 14 days in the damage control group (**[Figure 4](#F4){ref-type="fig"}**). The expression of p-JNK was significantly higher in SP600125, zinc sulfate, and quercetin groups (*P* \< 0.01; **[Figure 4](#F4){ref-type="fig"}**). The expression of p-JNK and p-c-Jun in the LGN was the same compared with that of 7 days in the retina from the damage control group (**[Figure 4](#F4){ref-type="fig"}**).

![Effects of laser treatment on the protein expression of phosphorylated c-Jun N-terminal kinases (p-JNK) and phosphorylated c-Jun (p-c-Jun) in retinal ganglion cells (RGCs) and the lateral geniculate nucleus (LGN) of rats after drug intervention.\
(A, B) The expression of p-JNK and p-c-Jun with different drug treatment groups in the retina at 7 days. (A, C) The expression of p-JNK and p-c-Jun with different drug treatment groups in the LGN at 14 days. The expression of p-c-Jun is significantly different between all four groups, 7 and 14 days after treatment. *P* \< 0.05, damage control group *vs.* the other three groups. I: Normal control group; II: damage control group; IV: zinc sulfate group; III: SP600125 group; V: quercetin group.](NRR-9-1395-g005){#F4}

Discussion {#sec1-4}
==========

The preinduction of HSPs in RGCs enhances the survival of RGCs under hypoxic, excitotoxic, and glaucomatous stress (Windisch et al., 2009; Yamashima, 2012). In this study, we showed that the major inducible chaperone within the HSP70 family, HSP72, protects RGCs and LGN neurons in rat models of chronic ocular hypertension from injury. We further found that the protection was related to the inhibition of SAPK/JNK pathway. This is the first report to demonstrate that chronic ocular hypertension induces HSP72 in retinal neurons, and it provides evidence of a neuroprotective effect for RGCs and LGN neurons in a chronic ocular hypertensive rat model.

Protective effect of HSP72 activation on RGCs and LGN neurons {#sec2-12}
-------------------------------------------------------------

Studies have shown that cells synthesize HSPs under physiological or environmental stress, such as hyperthermia and hypoxia, and in the presence of cytokines and other toxics (Tanaka et al., 2009; Lunz et al., 2013). HSPs enhance cell survival under conditions of further severe stress. HSP72 is expressed during preconditioning stress, and is known to be essential for neuroprotection (Yao et al., 2007; Carmeli et al., 2010). The upregulation of HSP72 enhances the survival of RGCs and LGN (Ebrahimi et al., 2010; Sohn et al., 2010). The expression level correlates positively with the extent and duration of stress (Ortega et al., 2012).

In the present study, we found that the expression of HSP72 in RGCs and LGN was greatly upregulated when glaucoma model rats were treated with laser photocoagulation. Ischemic-mediated stress and mechanical compression occurred in RGCs. HSP72 was induced in the cells. The expression level reached its peak at 3 days and disappeared at 28 days. Further, the expression of HSP72 in RGCs and LGN was elevated when rats were treated with zinc administration. However, administration with quercetin inhibited the expression of HSP72 and blocked the protection for RGCs and LGN neurons.

The rat glaucoma model used here showed mild to moderate loss of RGCs and LGN (indicating cell death) and mild axonal damage in chronic intraocular hypertension models.

Inhibition of SAPK/JNK pathway enhances the survival of RGCs and LGN neurons {#sec2-13}
----------------------------------------------------------------------------

SAPK/JNK belongs to the MAP kinase superfamily and regulates many cellular events (You et al., 2013). The SAPK/JNK signal transduction pathway is involved in the expression of interferon and participates in cell proliferation, differentiation, apoptosis, and immune regulation process (Pereira et al., 2012; Kondo et al., 2013). Numerous studies have confirmed that p-c-Jun levels are significantly decreased by the SAPK/JNK pathway inhibitor, SP600125 (Yao et al., 2010).

In the present study, zinc sulfate increased the expression of HSP72 and decreased c-Jun activation of the SAPK/JNK pathway. However, quercetin inhibited the expression of HSP72 and increased p-c-Jun. These results suggest that HSP72 blocks the apoptotic events associated with the SAPK/JNK pathway like SP600125. HSP72 also enhanced RGC and LGN neuron survival through SAPK/JNK pathway.

This study shows HSP72 and SP600125 protects RGCs and LGN from injury by blocking the activation of the SAPK/JNK pathway. Quercetin inhibited the expression of HSP72 and increased the activation of c-Jun in the LGN. Results from the present study provide a better understanding of the mechanisms underlying chronic glaucoma.

These findings suggest that gradually increasing the intraocular pressure, and intraperitoneal injection of zinc sulfate, contribute to increase of the expression of HSP72. By blocking the apoptotic SAPK/JNK pathway, HSP72 may play a protective role on RGC and the LGN in chronic ocular hypertensive rats.
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